Skip to main content

DESARROLLO DE UNA FIRMA EPIGENETICA EN BIOPSIA LIQUIDA PARA PREDECIR LA RESPUESTA TERAPEUTICA EN CANCER COLORRECTAL METASTASICO.

PI18/00307

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Epigenomic Analysis Reveals a Unique DNA Methylation Program of Metastasis-Competent Circulating Tumor Cells in Colorectal Cancer

  • Bao-Caamano, Aida
  • Costa-Fraga, Nicolás
  • Cayrefourcq, Laure
  • Jácome, M. A.
  • Rodríguez-Casanova, Aitor
  • Muinelo Romay, Laura
  • López-López, Rafael
  • Alix-Panabières, Catherine
  • Díaz-Lagares, Ángel
[Abstract] Circulating tumor cells (CTCs) and epigenetic alterations are involved in the development of metastasis from solid tumors, such as colorectal cancer (CRC). The aim of this study was to characterize the DNA methylation profile of metastasis-competent CTCs in CRC. The DNA methylome of the human CRC-derived cell line CTC-MCC-41 was analyzed and compared with primary (HT29, Caco2, HCT116, RKO) and metastatic (SW620 and COLO205) CRC cells. The association between methylation and the transcriptional profile of CTC-MCC-41 was also evaluated. Differentially methylated CpGs were validated with pyrosequencing and qMSP. Compared to primary and metastatic CRC cells, the methylation profile of CTC-MCC-41 was globally different and characterized by a slight predominance of hypomethylated CpGs mainly distributed in CpG-poor regions. Promoter CpG islands and shore regions of CTC-MCC-41 displayed a unique methylation profile that was associated with the transcriptional program and relevant cancer pathways, mainly Wnt signaling. The epigenetic regulation of relevant genes in CTC-MCC-41 was validated. This study provides new insights into the epigenomic landscape of metastasis-competent CTCs, revealing biological information for metastasis development, as well as new potential biomarkers and therapeutic targets for CRC patients., This research was funded by the ISCIII (PI18/00307) and the European Regional Development Fund (FEDER), and by the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. We would like to thank all donors who participated in the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. AB-C is funded by a predoctoral contract PFIS (FI19/00240) from “Instituto de Salud Carlos III” (ISCIII) co-funded by “Fondo Social Europeo” (FSE). NC-F is funded by a predoctoral contract from “Xunta de Galicia” (IN606A-2020/004). AR-C is supported by the Roche-Chus Joint Unit (IN853B 2018/03) funded by “Axencia Galega de Innovación (GAIN), Vicepresidencia Segunda e Consellería de Economía, Empresa e Innovación”. LM-R is funded by a contract “Miguel Servet” from ISCIII (CP20/00129). CA-P is supported by funding from the European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant agreement No. 765492, by The National Institute of Cancer (INCa, http://www.e-cancer.fr), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, and the ERA-NET TRANSCAN 2 JTC 2016 PROLIPSY, la Fondation ARC pour la Recherche sur le cancer and les Fonds de dotation AFER pour la recherche médicale. AD-L was funded by a contract “Juan Rodés” (JR17/00016) from “Instituto de Salud Carlos III” (ISCIII) and by Servizo Galego de Saúde (SERGAS). All authors have read the journal's policy on disclosure of potential conflicts of interest, and have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described research, Xunta de Galicia; IN606A-2020/004, Xunta de Galicia; IN853B 2018/03, Francia. Institut National du Cancer; INCa_Inserm_DGOS_12553
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modulation of colorectal tumor behavior via lncRNA TP53TG1-lipidic nanosystem

  • Masoumi, Farimah
  • Saraiva, Sofia M.
  • Bouzo, Belén L.
  • López-López, Rafael|||0000-0002-2240-6277
  • Esteller, M|||0000-0003-4490-6093
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
  • de la Fuente, María
Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA

  • Ruiz Bañobre, Juan|||0000-0003-0755-4295
  • Rodríguez Casanova, Aitor|||0000-0002-9828-3613
  • Costa-Fraga, Nicolás|||0000-0002-0869-8509
  • Bao Caamano, Aida
  • Álvarez Castro, Ana
  • Carreras Presas, Martín
  • Brozos Vázquez, Elena
  • Vidal Insua, Yolanda
  • Vázquez Rivera, Francisca
  • Candamio Folgar, Sonia|||0000-0003-4007-5990
  • Mosquera Presedo, Manuel|||0000-0002-9802-1082
  • Lago Lestón, Ramón M.|||0000-0002-1166-7754
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
  • Vázquez Bueno, José Ángel
  • Sanz Pamplona, Rebeca|||0000-0002-2187-3527
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Goel, Ajay|||0000-0003-1396-6341
  • Castillo, Lourdes
  • Martín, Ana C.
  • Arroyo, Rocío
  • Esteller, M.|||0000-0003-4490-6093
  • Crujeiras, Ana B.|||0000-0003-4392-0301
  • López López, Rafael|||0000-0003-1315-655X
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
Background: Current noninvasive assays have limitations in the early detection of colorectal cancer. We evaluated the clinical utility of promoter methylation of the long noncoding RNA LINC00473 as a noninvasive biomarker to detect colorectal cancer and associated precancerous lesions. Methods: We evaluated the epigenetic regulation of LINC00473 through promoter hypermethylation in colorectal cancer cell lines using bisulfite genomic sequencing and expression analyses. DNA methylation of LINC00473 was analyzed in primary colorectal tumors using 450K arrays and RNA-seq from The Cancer Genome Atlas (TCGA). Tissue-based findings were validated in several independent cohorts of colorectal cancer and advanced colorectal polyp patients by pyrosequencing. We explored the clinical utility of LINC00473 methylation for the early detection of colorectal cancer in plasma cell-free DNA by quantitative methylation-specific PCR and droplet digital PCR. Results: LINC00473 showed transcriptionally silencing due to promoter hypermethylation in colorectal cancer cell lines and primary tumors. Methylation of the LINC00473 promoter accurately detected primary colorectal tumors in two independent clinical cohorts, with areas under the receiver operating characteristic curves (AUCs) of 0.94 and 0.89. This biomarker also identified advanced colorectal polyps from two other tissue-based clinical cohorts with high diagnostic accuracy (AUCs of 0.99 and 0.78). Finally, methylation analysis of the LINC00473 promoter in plasma cell-free DNA accurately identified patients with colorectal cancer and advanced colorectal polyps (AUCs of 0.88 and 0.84, respectively), which was confirmed in an independent cohort of patients. Conclusions: Hypermethylation of the LINC00473 promoter is a new promising biomarker for noninvasive early detection of colorectal cancer and related precancerous lesions.